Euformatics named one of Finland’s fastest-growing technology companies in Deloitte Technology Fast 50 — achieving strong growth with sustained profitability
Espoo, Finland — October 2025. Euformatics has been recognized as one of Finland’s fastest-growing technology companies, earning a place on the Deloitte Technology Fast 50 Finland list for 2025. The annual ranking highlights the 50 tech companies in Finland with the highest revenue growth over the past four years (2021–2024). Euformatics ranked #48 with 225% revenue growth during the measurement period. What makes this recognition especially significant is that Euformatics achieved this growth while remaining profitable every single year — a rare distinction in a list largely dominated by companies posting financial losses in pursuit of scale.
Growth in clinical genomics
Euformatics develops and delivers software for clinical genomics, helping hospitals and diagnostic laboratories transform raw sequencing data into accurate, accredited, and actionable results for patient care. Our solutions support laboratories around the world in:
Ensuring reliable and accurate patient reporting through integrated quality control and NGS test validation
Between 2021 and 2024, the company experienced strong organic growth as genomic testing became increasingly integrated into mainstream healthcare. Clinical genomics transitioned from a specialized research activity to a core diagnostic tool — especially in oncology, rare diseases, and inherited disorders.
A rare combination: growth and profitability
The Deloitte Technology Fast 50 ranking is based purely on revenue growth, not profitability. This makes Euformatics’ performance particularly noteworthy — one of the few companies on the list to have achieved significant growth while operating profitably every year from 2021 to 2024.
“Achieving a place on the Deloitte Fast 50 list is a great recognition for our team and our customers,” said Tommi Kaasalainen, CEO of Euformatics.
“What makes me most proud is that we have managed to grow rapidly without sacrificing profitability or sustainability. In the current tech landscape, that’s rare — but for us, it reflects the trust that clinical laboratories place in our software and the long-term value we’re creating for healthcare. This recognition belongs equally to our dedicated team and to the customers who rely on us every day to make genomics work in real-world diagnostics.”
Growth driven by innovation and collaboration
Euformatics’ growth has been powered by a combination of product innovation, trusted customer relationships, and global collaboration in advancing clinical genomics standards.
Among our valued customers is Cerba Healthcare, one of Europe’s leading networks of medical laboratories. Cerba uses Euformatics software as part of its clinical diagnostics operations — supporting accurate, standardized variant interpretation in daily patient testing. Working with a group that processes millions of samples each year provides real-world validation of our products’ scalability, robustness, and regulatory readiness.
Our commitment to improving data quality in genomics also extends beyond our clinical customers. Euformatics has worked closely for the past decade with international quality assessment organizations such as EMQN (European Molecular Genetics Quality Network) and GenQA to assess the performance of clinical NGS laboratories globally. Through these partnerships, we contribute software tools, domain expertise, and automation solutions that support external quality assessment (EQA) schemes — helping laboratories worldwide measure and improve their performance in bioinformatics workflows.
Looking ahead
Being included in the Deloitte Technology Fast 50 list is both a milestone and a motivation. As precision medicine continues to expand globally, Euformatics remains focused on helping laboratories and healthcare systems scale genomics safely, efficiently, and affordably.
“Our mission has always been to make genomic data interpretation accurate, standardized, and accessible,” added Kaasalainen. “We’ll continue to invest in products and partnerships that make that vision a reality — sustainably.”
